Holen Sie sich die Stockscreener-App
3.20
1.54%
-0.05
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year HighHere's What Happened - MarketBeat
NMRA: NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and cash runway support growth - TradingView
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora - TipRanks
Neumora Therapeutics, Inc. Presents NMRA-511 Efficacy at Biotech Summit - TradingView
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st
Neumora Therapeutics (NASDAQ:NMRA) Trading Up 25.3%What's Next? - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Resistance Check: Should I buy Neumora Therapeutics Inc stock nowPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2% - MarketBeat
ETF Watch: Will Neumora Therapeutics Inc stock go up in YEAR2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Year in Review & Growth Focused Entry Reports - mfd.ru
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat
Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn
Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
RSI Check: Is Neumora Therapeutics Inc benefiting from innovation trends2025 Short Interest & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Wrap: Is Castle Biosciences Inc vulnerable to short sellersVolume Spike & Breakout Confirmation Alerts - baoquankhu1.vn
Why Neumora Therapeutics Inc stock appeals to analystsProduct Launch & Smart Allocation Stock Reports - Bộ Nội Vụ
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of Neumora Therapeutics (NMRA) with Outperform Recommendation - Nasdaq
Leerink Partners Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Leerink Initiates Neumora Therapeutics at Outperform With $8 Price Target - marketscreener.com
Neumora outlines 2026 neuroscience pipeline and obesity plans - TipRanks
Neumora Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating - TipRanks
Leerink Partners initiates coverage on Neumora stock with Outperform rating By Investing.com - Investing.com Canada
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is Neumora Therapeutics Inc. stock a defensive play in 2025Gap Down & Advanced Technical Analysis Signals - Улправда
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances - RTTNews
Published on: 2026-01-12 18:50:31 - ulpravda.ru
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Trend Review: What hedge fund activity signals for Neumora Therapeutics Inc. stockJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterVolume Analysis Techniques & Turn Data into Profits With Our Strategies - Улправда
How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine - Investor's Business Daily
Mizuho reiterates Outperform rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY) - The Globe and Mail
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora's Alzheimer's Agitation Drug Shows Early Promise - Sahm
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Nigeria
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com South Africa
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study - Nasdaq
Neumora outlines 2026 pipeline milestones for neuroscience programs - Investing.com
Neumora posts trial results for Alzheimer’s drug (NMRA:NASDAQ) - Seeking Alpha
Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation - Nasdaq
Neumora reports promising Phase 1b results in Alzheimer’s agitation - TipRanks
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):